The conversation of VLR has sparked a discussion as to whether or not other COVID-19 treatment agents are associated with a surge in symptoms and if so, how those agents compare with the rebound effect of nirmatrelvir/ritonavir.
Sarah Hughes, PharmD
Advertisement
Articles by Sarah Hughes, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
From Stigma to Breakthrough: Psychedelic Medicine
2
CHEST 2025: Brensocatib Shows Potential to Slow Structural Lung Changes in Bronchiectasis
3
Pharmacists Can Drive Equitable Diagnostics Access, Improve Antimicrobial Resistance Stewardship
4
In the Fragmented Landscape of Long COVID Care, Pharmacists Are Essential
5
